Also consider;; RCW treatment should be eligible for BTD ,, especially if P2 improves efficacy over P1...
I've been trading CLSN very successfully, but I'm looking for a good research site to get stock picks from. I've made a lot of money (over $60k) from UA (underground stock alerts*) google them - looking for more solid research sites to add to my trading arsenal. please leave your recommendations below along with a review, i think this will be beneficial to all traders here on the board. thanks and good luck to all!
April 9th Zacks announces CLSN entering oversold @ 3.31. June 17th Zacks pronounces CLSN overbought @ 3.50. In the interim CLSN achieves FDA consent for ph3b Optima trial & obtains a viable/compatable privately held co. Sooo…where's the credibility? Imo, Zacks has zero.
Right. That way we can hit 10 billion instead of only 8. We have the same policy in all third world countries.
I agree, nothing works on multiple HCC tumors, but on single HCC tumors 3-7 cm, Tdox does better than 55% over the current SOC.
On RCW tumors, Tdox efficacy is over 40%, where SOC is end of life pain medication.
And Celsion is working on other difficult to treat cancers such as brain and painful bone metastasis cancer, or when cancer spreads to the bone.
HIFU news could come at any time. Nothing that would move the stock price though.
See clinical trials website, RCW will conclude at the end of the year. Phase I had efficacy of 50% over SOC. SOC for RCW is morphine and hospice. Similar phase II results of 50% will move the pps. Those results should come Dec 2014 to Feb 2015.
And Optima. I will be two years or so before the DMC have an in process review of the clinical trial. A year later they will take another look. Tdox's safety profile is already well established, so the trial could be halted at either one of those reviews.
A lot of investors have given up on Celsion. What they fail to realize is that nothing works on multiple liver tumors. It appears there may be hope with single tumors.
Celsion is working on other indications like bone metastases and they just bought another technology that I am not up to speed on yet, but seems to be a big deal of sorts.
Good luck all.
This is an interesting endeavor, however I have a question about the trial that I need clarification on. You state that each patient must have at least three tumors to participate. Are these patients then divided up into three different groups or are each patients tumors treated as three separate groups? If the later is true, then how will test two and three be differentiated since the doxorubicin is injected interveinously? Wouldn't that negate the RFA alone treatment since the liposomes would be throughout the entire body? Can you explain this further for me? Thank you.